Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2019

View Archived Issues

New antibody against F glycoprotein prevents membrane fusion and viral entry in NiV, HeV infections

Novel dietary-induced mouse model of NASH with severe fibrosis

Celldex reports results from ongoing phase I study of CDX-1140

Enrollment ongoing in phase III study of TV P2-VP8 vaccine

Pfizer initiates phase III study of PF-06741086

Phase IIb ATLAS study of etokimab fails to meet the primary endpoint

Update given for the phase III JAVELIN gastric 100 trial

UMC Utrecht Holding discloses thombolytic fusion proteins

IL-38 protein compositions described by Reyoung Suzhou Biology Science & Technology

FORMA Therapeutics discovers histone deacetylase 11 inhibitors

Medshine Discovery patents Rho kinase inhibitors

Roche and Genentech identify new RIP-1 inhibitors

Simpler recipe makes better cocktail for iPSCs

Exosomes help brain metastases along

Novel AVV-based vector therapy for the treatment of AD

New DREADD tools for noninvasive manipulation and visualization of neuronal circuits in animals

Zelluna Immunotherapy presents novel compound, ZI-H04, as cancer immunotherapeutic

Glecaprevir/pibrentasvir investigated in young children with chronic HCV infection

Now, Sleeping Beauty is the fairest of them all

NKTR-358 safe and well tolerated in first-in-human study

SUNFISH study of risdiplam in type 2 and 3 SMA meets primary endpoint

FDA approves Reblozyl for anemia in beta thalassemia requiring regular RBC transfusions

First-in-human comparison of LY-2775240 and apremilast in healthy volunteers

New phase IIa study investigates use of MTPS-9579A in asthma

Lyvgen initiates first-in-human study of LVGN-6051 in advanced or metastatic malignancy

Roche announces discontinuation of RG-6206 development in DMD

Oncogene-linked prodrug strategy for selective KEAP1 mutant NSCLC cytotoxicity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...